Quick Answer
Voyager Therapeutics, Inc. reported Total Revenue of $40.37 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed a decrease of -49.5% in Total Revenue from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2015 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $2.58 million | Q2 2015: $4.88 million | Q3 2015: $4.94 million | Q4 2015: $4.94 million | Q1 2016: $4.83 million | Q2 2016: $3.72 million | Q3 2016: $3.31 million | Q4 2016: $2.36 million | Q1 2017: $1.46 million | Q1 2017: $1.46 million | Q2 2017: $1.18 million | Q2 2017: $1.18 million | Q3 2017: $1.15 million | Q3 2017: $1.15 million | Q4 2017: $6.35 million | Q4 2017: $6.35 million | Q1 2018: $942.0 thousand | Q1 2018: $942.0 thousand | Q2 2018: $2.58 million | Q2 2018: $2.58 million | Q3 2018: $2.09 million | Q3 2018: $2.09 million | Q4 2018: $2.01 million | Q1 2019: $5.20 million | Q2 2019: $46.09 million | Q3 2019: $20.43 million | Q4 2019: $32.67 million | Q1 2020: $18.07 million | Q2 2020: $28.68 million | Q3 2020: $117.84 million | Q1 2021: $6.50 million | Q2 2021: $1.36 million | Q3 2021: $1.48 million | Q1 2022: $658.0 thousand | Q2 2022: $712.0 thousand | Q3 2022: $41.09 million | Q1 2023: $150.48 million | Q2 2023: $4.85 million | Q3 2023: $4.61 million | Q1 2024: $19.52 million | Q2 2024: $29.58 million | Q3 2024: $24.63 million | Q1 2025: $6.47 million | Q2 2025: $5.20 million | Q3 2025: $13.37 million.
- Over the full 13 years of available data (2015 to 2025), Voyager Therapeutics, Inc.'s Total Revenue has grown by 132.9%.
- Historical annual values: Fiscal year 2025: $40.37 million | Fiscal year 2024: $80.00 million | Fiscal year 2023: $250.01 million | Fiscal year 2022: $40.91 million | Fiscal year 2021: $37.42 million | Fiscal year 2020: $171.13 million | Fiscal year 2019: $104.39 million | Fiscal year 2018: $7.62 million | Fiscal year 2017: $10.14 million | Fiscal year 2017: $10.14 million | Fiscal year 2016: $14.22 million | Fiscal year 2016: $14.22 million | Fiscal year 2015: $17.33 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: